Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02181 MABPHARM-B
RT Nominal up0.280 +0.005 (+1.818%)
Latest  |  Final  |  Interim
Non-current Assets
2024/06 - Interim
RMB(K¥)
%Chg
(Compare to Final)
2023/12
RMB(K¥)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
Investment Properties0--0000
Property, plant, equip. & others590,824-3.967%615,232636,306483,673438,408
Land & other Lease Assets66,684-6.479%71,30467,70777,37474,209
Intangible Assets0--0000
Interests in Asso. & JCEs0--0000
Other Non-current Assets5,816-6.660%6,23112,38891,08581,294

663,324-4.250%692,767716,401652,132593,911
Current Assets
2024/06 - Interim
RMB(K¥)
%Chg
(Compare to Final)
2023/12
RMB(K¥)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
Inventories101,703-0.327%102,037100,79753,21133,427
Trade Receivables64,151230.284%19,4239,5327930
Cash & Bank Balances74,066-57.272%173,34533,56881,556484,846
Other Current Assets43,150-8.968%47,40157,223112,21050,853
Assets Held for Sale0--0000

283,070-17.281%342,206201,120247,770569,126
Current Liabilities
2024/06 - Interim
RMB(K¥)
%Chg
(Compare to Final)
2023/12
RMB(K¥)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
Trade Payables12,24622.313%10,01216,58612,8604,466
S-T Debt & Leases48,072-61.622%125,25813,2919,2838,532
Other Current Liabilities204,99413.306%180,921158,524212,861189,629
Liab asso w/ Assets Held for Sale0--0000

265,312-16.091%316,191188,401235,004202,627
Net Current Assets17,758-31.739%26,01512,71912,766366,499
Total Assets Less Current Liabilities681,082-5.245%718,782729,120664,898960,410
Non-current Liabilities
2024/06 - Interim
RMB(K¥)
%Chg
(Compare to Final)
2023/12
RMB(K¥)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
L-T Debt & Leases195,56045.058%134,815113,04636,40731,816
Other Non-current Liabilities370,331-2.264%378,910215,13026,51047,109

565,89110.154%513,725328,17662,91778,925
Capital and Reserves
2024/06 - Interim
RMB(K¥)
%Chg
(Compare to Final)
2023/12
RMB(K¥)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
  Share Capital2,8040.000%2,8042,8042,8042,804
  Reserves112,387-44.432%202,253398,140599,177878,681
  Others0--0000
Shareholders' Funds115,191-43.825%205,057400,944601,981881,485
Non-controlling Interests0--0000
Others0--0000

115,191-43.825%205,057400,944601,981881,485
Commitments and Contingent Liabilities
2024/06 - Interim
RMB(K¥)
%Chg
(Compare to Final)
2023/12
RMB(K¥)
2022/12
RMB(K¥)
2021/12
RMB(K¥)
2020/12
RMB(K¥)
Commitments----3,97820,760138,649138,014
Contingent Liabilities----0000
Remarks:  Real time quote last updated: 27/12/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
Security Code
Company Name (Chi/Eng/Keywords)
Industry
Profit / (Loss) Attributable to Shareholders (¥)RMB -97,569,000
%Change-2.430%
EPS / (LPS)RMB -0.020
NBV Per Share (¥)RMB 0.028
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.